Alphamab Oncology ( ($HK:9966) ) has shared an update. Alphamab Oncology announced that its Investigational New Drug application for JSKN022, a ...

There’s a lot to say about the economy and markets today. Earnings season is well underway, with 317 S&P 500 companies having ...

The breakome is a new layer in the multiomics landscape—alongside the genome, transcriptome, proteome, and interactome. While it hasn’t traditionally been included among these other omics, we consider ...

Advances in instruments and tools, as well as focused collaborations, improve accuracy and extend the range of applications.

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

When surgeons repair tissues, they're currently limited to mechanical solutions such as sutures and staples, which can cause their own damage, or meshes and glues that may not adequately bond with ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

The court should adopt a narrow view of the Mann Act, the legal team states in a new filing, calling its application in Sean ...

After a decade of development, a Kansas City-based pharmaceutical company is on the brink of submitting its ADHD medication ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

The key news from the release was that while the company outperformed revenue estimates—reporting $28.2 million (GAAP) compared to the expected $27.03 million—profitability came under pressure, with a ...